PEtOx-DOPE nanoliposomes functionalized with peptide 563 in targeted BikDDA delivery to prostate cancer
![Thumbnail](/xmlui/bitstream/handle/20.500.12960/1666/PEtOx-DOPE%20nanoliposomes%20functionalized%20with%20peptide%20563%20in%20targe.pdf.jpg?sequence=4&isAllowed=y)
View/ Open
Access
info:eu-repo/semantics/openAccessDate
2024Author
Nezir, Ayca EceBolat, Zeynep Büşra
Saka, Ongun Mehmet
Zemheri, Itır Ebru
Gülyüz, Sevgi
Özköse, Umut Uğur
Yilmaz, Özgür
Bozkir, Asuman
Şahin, Fikrettin
Telci, Dilek
Metadata
Show full item recordCitation
Nezir, A. E., Bolat, Z. B., Saka, O. M., ZEMHERİ, I. E., Gülyüz, S., Özköse, U. U., ... & Telci, D. (2024). PEtOx-DOPE nanoliposomes functionalized with peptide 563 in targeted BikDDA delivery to prostate cancer. Turkish Journal of Biology, 48(3), 174-181.Abstract
Background: Nanocarrier-based systems have cultivated significant improvements in prostate cancer therapy. However, the efforts are still limited in clinical applicability, and more research is required for the development of effective strategies. Here, we describe a novel nanoliposomal system for targeted apoptotic gene delivery to prostate cancer. Methods: Poly (2-ethyl-2-oxazoline) (PEtOx) dioleoyl phosphatidylethanolamine (DOPE) nanoliposomes were conjugated with the prostate-specific membrane antigen (PSMA)-targeting peptide GRFLTGGTGRLLRIS (P563) and loaded with BikDDA, a mutant form of the proapoptotic Bik. We selected 22Rv1 cells with moderate upregulation of PSMA to test the in vitro uptake, cell death, and in vivo anticancer activity of our formulation, P563-PEtOx-DOPE-BikDDA. Results: BikDDA was upregulated in 22Rv1 cells, inducing cell death, and CD-1 nude mice xenografts administered with the formulation showed significant tumor regression. Conclusion: We suggest that P563-PEtOx-DOPE-BikDDA nanoliposomes can serve as prominent gene carriers against prostate cancer.